JP2019524774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524774A5 JP2019524774A5 JP2019505256A JP2019505256A JP2019524774A5 JP 2019524774 A5 JP2019524774 A5 JP 2019524774A5 JP 2019505256 A JP2019505256 A JP 2019505256A JP 2019505256 A JP2019505256 A JP 2019505256A JP 2019524774 A5 JP2019524774 A5 JP 2019524774A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- ocs
- pharmaceutical composition
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 201000004624 Dermatitis Diseases 0.000 claims 13
- 239000003961 penetration enhancing agent Substances 0.000 claims 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- 201000008220 erythropoietic protoporphyria Diseases 0.000 claims 6
- 229920002125 Sokalan® Polymers 0.000 claims 5
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 claims 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 125000005456 glyceride group Chemical group 0.000 claims 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 4
- 239000004584 polyacrylic acid Substances 0.000 claims 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 4
- 206010040882 skin lesion Diseases 0.000 claims 4
- 231100000444 skin lesion Toxicity 0.000 claims 4
- 206010015150 Erythema Diseases 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- PIUZYOCNZPYXOA-ZHHJOTBYSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 PIUZYOCNZPYXOA-ZHHJOTBYSA-N 0.000 claims 3
- 231100000321 erythema Toxicity 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 239000002562 thickening agent Substances 0.000 claims 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 2
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 claims 2
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 claims 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- 239000005642 Oleic acid Substances 0.000 claims 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims 2
- 229960000541 cetyl alcohol Drugs 0.000 claims 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 229960004756 ethanol Drugs 0.000 claims 2
- -1 fatty acid esters Chemical class 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 150000002191 fatty alcohols Chemical class 0.000 claims 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- 229940067606 lecithin Drugs 0.000 claims 2
- 210000003924 normoblast Anatomy 0.000 claims 2
- 229940049964 oleate Drugs 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 150000003077 polyols Chemical class 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229940026235 propylene glycol monolaurate Drugs 0.000 claims 2
- 229950006451 sorbitan laurate Drugs 0.000 claims 2
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical class C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Chemical class 0.000 claims 1
- 125000005250 alkyl acrylate group Chemical class 0.000 claims 1
- 229940086737 allyl sucrose Drugs 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 239000001913 cellulose Chemical class 0.000 claims 1
- 229920002678 cellulose Chemical class 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002449 erythroblastic effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Chemical class 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021185644A JP2022031733A (ja) | 2016-08-02 | 2021-11-15 | 炎症性皮膚疾患及び皮膚病変を処置するための酸素化コレステロール硫酸（ｏｃｓ）の使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370036P | 2016-08-02 | 2016-08-02 | |
| US62/370,036 | 2016-08-02 | ||
| US201762470576P | 2017-03-13 | 2017-03-13 | |
| US62/470,576 | 2017-03-13 | ||
| PCT/US2017/044821 WO2018026767A1 (en) | 2016-08-02 | 2017-08-01 | Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021185644A Division JP2022031733A (ja) | 2016-08-02 | 2021-11-15 | 炎症性皮膚疾患及び皮膚病変を処置するための酸素化コレステロール硫酸（ｏｃｓ）の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019524774A JP2019524774A (ja) | 2019-09-05 |
| JP2019524774A5 true JP2019524774A5 (enExample) | 2020-08-27 |
Family
ID=61073120
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505256A Pending JP2019524774A (ja) | 2016-08-02 | 2017-08-01 | 炎症性皮膚疾患及び皮膚病変を処置するための酸素化コレステロール硫酸（ｏｃｓ）の使用 |
| JP2021185644A Pending JP2022031733A (ja) | 2016-08-02 | 2021-11-15 | 炎症性皮膚疾患及び皮膚病変を処置するための酸素化コレステロール硫酸（ｏｃｓ）の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021185644A Pending JP2022031733A (ja) | 2016-08-02 | 2021-11-15 | 炎症性皮膚疾患及び皮膚病変を処置するための酸素化コレステロール硫酸（ｏｃｓ）の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190374554A1 (enExample) |
| EP (1) | EP3493671A4 (enExample) |
| JP (2) | JP2019524774A (enExample) |
| KR (2) | KR20230124756A (enExample) |
| CN (1) | CN109862787A (enExample) |
| AU (2) | AU2017306140A1 (enExample) |
| BR (1) | BR112019001193A2 (enExample) |
| CA (1) | CA3031211A1 (enExample) |
| IL (1) | IL264389A (enExample) |
| MX (1) | MX2019001324A (enExample) |
| TW (2) | TW202308651A (enExample) |
| WO (1) | WO2018026767A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| EP3086793B1 (en) | 2013-12-24 | 2022-05-11 | Virginia Commonwealth University | Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction |
| KR102593667B1 (ko) | 2016-08-02 | 2023-10-24 | 버지니아 커먼웰스 유니버시티 | 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물 |
| CA3170320A1 (en) * | 2020-02-11 | 2021-08-19 | Durect Corporation | Treatment of infectious diseases |
| EP4203958A4 (en) * | 2020-08-26 | 2024-10-09 | Oticara, Inc. | COMPOSITIONS, DEVICES AND METHODS FOR TREATING NOSE, EAR AND OTHER TISSUE INFECTIONS AND/OR INFECTIONS |
| CN113040140B (zh) * | 2021-01-28 | 2022-06-03 | 菲吉乐科(南京)生物科技有限公司 | 一种适合噬菌体浸入藤本和木本植物用的辅助渗透剂及其制备方法和应用 |
| CN113521094A (zh) * | 2021-05-23 | 2021-10-22 | 广州奇维生物信息技术有限公司 | 一种治疗湿疹的乳剂软膏及其制备方法 |
| CN114646702B (zh) * | 2022-03-03 | 2023-01-06 | 四川大学华西医院 | 胆固醇硫酸酯检测试剂在制备脓毒症辅助诊断、治疗效果监测和预后评估试剂盒中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US4743597A (en) * | 1986-01-27 | 1988-05-10 | Javitt Norman B | Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases |
| US8399441B2 (en) | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| US20120253143A1 (en) * | 2011-04-04 | 2012-10-04 | Raphael Warren | Method of measuring a skin agent transferred to skin |
| CN106083976B (zh) * | 2012-04-12 | 2018-02-09 | 弗吉尼亚联邦大学 | 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS) |
| EP3086793B1 (en) * | 2013-12-24 | 2022-05-11 | Virginia Commonwealth University | Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction |
-
2017
- 2017-08-01 US US16/320,400 patent/US20190374554A1/en not_active Abandoned
- 2017-08-01 AU AU2017306140A patent/AU2017306140A1/en not_active Abandoned
- 2017-08-01 JP JP2019505256A patent/JP2019524774A/ja active Pending
- 2017-08-01 CA CA3031211A patent/CA3031211A1/en active Pending
- 2017-08-01 WO PCT/US2017/044821 patent/WO2018026767A1/en not_active Ceased
- 2017-08-01 TW TW111139507A patent/TW202308651A/zh unknown
- 2017-08-01 KR KR1020237027532A patent/KR20230124756A/ko not_active Withdrawn
- 2017-08-01 KR KR1020197005444A patent/KR102568036B1/ko active Active
- 2017-08-01 TW TW106125933A patent/TW201818944A/zh unknown
- 2017-08-01 BR BR112019001193-5A patent/BR112019001193A2/pt not_active Application Discontinuation
- 2017-08-01 MX MX2019001324A patent/MX2019001324A/es unknown
- 2017-08-01 CN CN201780048064.0A patent/CN109862787A/zh active Pending
- 2017-08-01 EP EP17837507.7A patent/EP3493671A4/en not_active Withdrawn
-
2019
- 2019-01-22 IL IL264389A patent/IL264389A/en unknown
-
2020
- 2020-10-16 US US17/072,994 patent/US20210169902A1/en not_active Abandoned
-
2021
- 2021-11-15 JP JP2021185644A patent/JP2022031733A/ja active Pending
-
2022
- 2022-07-13 AU AU2022205208A patent/AU2022205208A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524774A5 (enExample) | ||
| US11622945B2 (en) | Topical pharmaceutical compositions | |
| US10188672B2 (en) | Compositions and methods for tissue regeneration | |
| CN104994843B (zh) | 用于创伤愈合的成膜药物组合物和用于制备其的方法 | |
| JP2014530242A5 (enExample) | ||
| WO2018138737A1 (en) | Therapeutic topical compositions of apremilast | |
| EP2654745A1 (en) | Composition for the treatment of skin conditions | |
| US20180064656A1 (en) | Topical pharmaceutical compositions | |
| JP2019524774A (ja) | 炎症性皮膚疾患及び皮膚病変を処置するための酸素化コレステロール硫酸（ｏｃｓ）の使用 | |
| JP2011528700A5 (enExample) | ||
| CN108210462A (zh) | 一种克立硼罗局部缓释脂质体的制法与应用 | |
| CN101272786B (zh) | 含有吡啶酮羧酸衍生物的洗剂 | |
| CN102370673A (zh) | 苏冰(速效救心)喷雾剂及其制备方法 | |
| US12280031B2 (en) | Teriflunomide topical pharmaceutical compositions | |
| US20130197089A1 (en) | Compositions for the treatment of actinic keratosis | |
| EP2505195B1 (en) | Topical pharmaceutical compositions of ketoprofen and methylsulfonylmethane | |
| CN102525883A (zh) | 一种伏立康唑栓剂及其制备方法和用途 | |
| CA3183195A1 (en) | Topical pharmaceutical compositions | |
| WO2016161683A1 (zh) | 一种他汀类药物组合物及胶囊制剂、其制备方法 | |
| US20150025139A1 (en) | Ingenol mebutate in combination with cryotherapy for the treatment of actinic keratosis | |
| CA2973542C (en) | Enema for rectal application | |
| JP2024541690A (ja) | 医薬におけるｗｓ６３５の使用 | |
| CN107157993A (zh) | 一种治疗皮肤干燥的药物组合物及其制备方法 | |
| WO2016133471A1 (en) | A topical composition comprising mupirocin and dexpanthenol | |
| WO2021080527A1 (en) | Topical pharmaceutical compositions containing difluocortolone and isoconazole |